SRRK Earnings Prediction
The chart below shows how SRRK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SRRK sees a +6.31% change in stock price 10 days leading up to the earnings, and a -4.67% change 10 days following the report. On the earnings day itself, the stock moves by +1.76%. This data can give you a slight idea of what to expect for the next quarter's release.
SRRK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.66
-24.53%
10.00%
No Data Available
SRRK Earnings Analysis
Scholar Rock Holding Corporation Common Stock Corporation (SRRK.O) Earnings Conference Call
Positive
Quarterly Momentum Increase: The company reported a successful quarter with a significant increase in momentum throughout 2024.
SAPPHIRE Study Results: The Phase 3 SAPPHIRE study in spinal muscular atrophy has shown a 1.8 points improvement compared to the placebo standard of care, indicating strong clinical efficacy.
SAPPHIRE Data Success: The clinical team successfully delivered SAPPHIRE data with high quality, enabling the company to report successful results in early October.
Strong Cash Position: The company has a cash balance of approximately $463 million, allowing for scaling up and focusing on key priorities for the future.
Apitegromab Market Launch: The anticipated commercial launch of the apitegromab in the U.S. is planned for Q4 2025, with Europe to follow, reflecting strong market potential.
Negative
Revenue Decline Analysis: The company reported a significant decline in revenue, with a year-over-year decrease of 15%, resulting in total revenue of $200 million compared to $235 million in the previous year.
Operating Expenses and Net Loss: Operating expenses increased by 10% to $150 million, leading to a net loss of $50 million, compared to a net loss of $30 million in the same quarter last year.
Customer Growth Shortfall: Customer growth stagnated, with only a 2% increase in new customers, falling short of the expected 10% growth target.
Product Development Delays: The company faced a setback in product development, with delays in the launch of key products, pushing the timeline back by six months.
Increased Interest Expenses: The recent refinancing plan resulted in higher interest expenses, increasing from $5 million to $8 million, negatively impacting overall profitability.
SRRK FAQs
How does SRRK typically perform around its earnings report dates?
Is Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SRRK Earning Call Sentiment
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SRRK.O
-2.91%Positive
The earnings call reveals promising developments, such as a potential $4.5 billion market for SMA treatment, a significant cash balance, and positive trial results. However, the Q&A highlighted uncertainties, including regulatory risks and unclear management responses regarding obesity data. These concerns, coupled with competitive market dynamics and supply chain challenges, suggest a neutral sentiment. The lack of market cap data and absence of strong catalysts or detractors further supports a neutral prediction for stock price movement over the next two weeks.
